Symeres appoints Henning Steinhagen as CEO to drive next phase of global growth

Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints

Piramal Pharma Solutions appoints Gregory Judge as Director to strengthen European business

In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe

NIPER Hajipur, Boehringer Ingelheim India ink MoU to boost translational pharma research

As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.

Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Head Bioprocessing, India, Avantor

Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region

Crown Bioscience partners with Turbine to accelerate translational oncology research

The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems

Novartis CEO Vas Narasimhan joins Anthropic board

Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery

AWS unveils Amazon Bio Discovery to accelerate drug design with AI